Global, Multi-Center, Repeat-Dose, Phase 2 Study of RZ358 (ersodetug), an Insulin Receptor Antibody, for Congenital Hyperinsulinism
Med (New York, NY)(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined